ATRX and central nervous system cancer: They performed immunofluorescence assay using glioma cell model and discovered that FADD overexpression increased temozolomide (TMZ)-induced DNA damage in glioma cells, whereas FADD knockdown decreased TMZ-induced DNA damage in ATRX knockout glioma cells.